Patricia Grabowski

3.3k total citations
75 papers, 2.2k citations indexed

About

Patricia Grabowski is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Patricia Grabowski has authored 75 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 34 papers in Epidemiology and 21 papers in Neurology. Recurrent topics in Patricia Grabowski's work include Neuroendocrine Tumor Research Advances (33 papers), Lung Cancer Research Studies (22 papers) and Neuroblastoma Research and Treatments (17 papers). Patricia Grabowski is often cited by papers focused on Neuroendocrine Tumor Research Advances (33 papers), Lung Cancer Research Studies (22 papers) and Neuroblastoma Research and Treatments (17 papers). Patricia Grabowski collaborates with scholars based in Germany, United States and United Kingdom. Patricia Grabowski's co-authors include Hans Scherübl, Martin Zeitz, Carmen Scheibenbogen, Franziska Briest, Sandra Bauer, Michael Höpfner, Hans‐Dieter Volk, Kirsten Wittke, Helma Freitag and Harald Heidecke and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Patricia Grabowski

71 papers receiving 2.2k citations

Peers

Countries citing papers authored by Patricia Grabowski

Since Specialization

Citations

This map shows the geographic impact of Patricia Grabowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Grabowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Grabowski more than expected).

Fields of papers citing papers by Patricia Grabowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Grabowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Grabowski. The network helps show where Patricia Grabowski may publish in the future.

Co-authorship network of co-authors of Patricia Grabowski

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Grabowski. A scholar is included among the top collaborators of Patricia Grabowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Grabowski. Patricia Grabowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study 2025 ·Medicine ·(unknown), Sebastian Maasberg, Nehara Begum, Anja Rinke, Thorsten Pöppel, Bence Sipos, Christian Grohé, Christian Fottner, Sebastian Stintzing, Patricia Grabowski, (unknown)	1
2	Immune Checkpoint Blockade Combined with AbnobaViscum® Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence 2024 ·Pharmaceuticals ·Friedemann Schad, Anja Thronicke, Ralf‐Dieter Hofheinz, Reinhild Klein, Patricia Grabowski, Shiao Li Oei, (unknown), (unknown)	2
3	Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells 2024 ·Frontiers in Pharmacology ·(unknown), (unknown), (unknown), (unknown), (unknown), Franziska Briest, Liliana H. Mochmann, (unknown), (unknown), (unknown), Helma Freitag, (unknown), Hedwig Lammert, Svenja Nölting, Michael Hummel, Jörg Schrader, Patricia Grabowski	2
4	Does the Argentine Tango Sustainably Improve Cancer-Associated Fatigue and Quality of Life in Breast Cancer Survivors? 2023 ·Cancers ·Shiao Li Oei, Anja Thronicke, (unknown), (unknown), (unknown), Patricia Grabowski, Gerrit Grieb, Harald Matthes, Friedemann Schad	2
5	Self-Reported Baseline Quality of Life Mirrors Treatment-Specific Characteristics of Cancer Patients 2023 ·Cancers ·Anja Thronicke, Shiao Li Oei, Gerrit Grieb, Patricia Grabowski, (unknown), Friedemann Schad	0
6	Radiofrequency Electromagnetic Fields Cause Non-Temperature-Induced Physical and Biological Effects in Cancer Cells 2022 ·Cancers ·Peter Wust, (unknown), Eva Oberacker, Prabhu Srinivas Yavvari, Wolfgang Walther, Olof Bengtsson, Anja Sterner‐Kock, Marie Weinhart, Florian Heyd, Patricia Grabowski, Sebastian Stintzing, W. Heinrich, Ulrike Stein, Pirus Ghadjar	12
7	Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study 2021 ·Journal of Clinical Medicine ·Carmen Scheibenbogen, Franziska Sotzny, Jelka Hartwig, Sandra Bauer, Helma Freitag, Kirsten Wittke, Wolfram Doehner, Nadja Scherbakov, Madlen Loebel, Patricia Grabowski	7
8	Targeting HDACs in Pancreatic Neuroendocrine Tumor Models 2021 ·Cells ·(unknown), (unknown), (unknown), Jessica L. Bell, Stefan Hüttelmaier, (unknown), Till S. Clauditz, Patricia Grabowski, Helmut Laumen, Jonas Rosendahl, Patrick Michl, Jörg Schrader, Sebastian Krug	17
9	A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1 2020 ·Cancers ·Kim Barbara Luley, (unknown), Axel Künstner, Hauke Busch, Sören Franzenburg, Jörg Schrader, Patricia Grabowski, Ulrich F. Wellner, Tobias Keck, Georg Brabant, Sebastian Schmid, Hendrik Lehnert, Hendrik Ungefroren	34
10	Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo 2020 ·Neoplasia ·Franziska Briest, (unknown), Jakob Albrecht, (unknown), Monique R. Bernsen, Joost Haeck, Anja A. Kühl, (unknown), (unknown), (unknown), Martina Welzel, Christian Fischer, Carsten Grötzinger, Winfried Brenner, Richard P. Baum, Patricia Grabowski	9
11	Myalgic encephalomyelitis/chronic fatigue Syndrome (ME/CFS): Investigating care practices pointed out to disparities in diagnosis and treatment across European Union 2019 ·PLoS ONE ·Elin Bolle Strand, Luís Nacul, Anne Marit Mengshoel, Ingrid B. Helland, Patricia Grabowski, Angelika Krūmiņa, José Alegre, (unknown), Slobodan Sekulić, Derek Pheby, Giorgos K. Sakkas, Carmen Adella Sîrbu, François‐Jérôme Authier, (unknown)	22
12	Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model 2018 ·Molecular Cancer Research ·Daniel Benten, (unknown), (unknown), (unknown), Gerrit Wolters‐Eisfeld, Susanne Burdak‐Rothkamm, Felix R. Stahl, Martin Anlauf, Patricia Grabowski, Markus Möbs, Jan Dieckhoff, Bence Sipos, (unknown), (unknown), Daniel Pérez, Maximillian Bockhorn, Jakob R. Izbicki, Ansgar W. Lohse, Jörg Schrader	54
13	The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models 2017 ·PLoS ONE ·Svenja Nölting, (unknown), Helma Freitag, Katharina Detjen, Franziska Briest, Markus Möbs, (unknown), Britta Siegmund, Christoph J. Auernhammer, (unknown), Michael Lauseker, Ashley Grossman, (unknown), Christian Fischer, Carsten Grötzinger, Jörg Schrader, Patricia Grabowski, (unknown)	28
14	Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors 2017 ·Neuroendocrinology ·Franziska Briest, (unknown), (unknown), Markus Möbs, Friederike Christen, (unknown), (unknown), (unknown), Daniel Kaemmerer, Jörg Sänger, (unknown), (unknown), Helma Freitag, (unknown), (unknown), (unknown), Britta Siegmund, Wolfgang Walther, Michael Hummel, Patricia Grabowski	12
15	Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease 2016 ·Neuroendocrinology ·Helma Freitag, Friederike Christen, (unknown), (unknown), Franziska Briest, (unknown), Britta Siegmund, Patricia Grabowski	26
16	Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome 2015 ·Human Immunology ·(unknown), Madlen Loebel, Agnes A. Mooslechner, Michael Knops, Leif G. Hanitsch, Patricia Grabowski, Kirsten Wittke, Christian Meisel, Nadine Unterwalder, Hans‐Dieter Volk, Carmen Scheibenbogen	25
17	PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms 2014 ·Theranostics ·Franziska Briest, Patricia Grabowski	73
18	Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie 2009 ·Annals of Oncology ·Sylvie Lorenzen, Tibor Schuster, Rainer Porschen, S. Al-Batran, Ralf‐Dieter Hofheinz, Peter Thuss‐Patience, Markus Moehler, Patricia Grabowski, Dirk Arnold, Tim F. Greten, (unknown), Nadine Röthling, C. Peschel, Rupert Langer, Florian Lordick	169
19	ZM 447439, a novel promising aurora kinase inhibitor, provoking antiproliferative and pro-apoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor disease 2007 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Yawen Wang, (unknown), Martin Zeitz, Patricia Grabowski	1
20	Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis 2005 ·International Journal of Colorectal Disease ·Patricia Grabowski, Isrid Sturm, (unknown), Kerstin Maaser, H. J. Buhr, Bernd Dörken, Martin Zeitz, Peter T. Daniel, Hans Scherübl	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact